论文部分内容阅读
生物制品批签发是国家药品管理机构或其授权单位根据批生产检定记录的审核和试验检测的结果,对即将上市销售的生物制品进行批放行的制度,是生物制品大规模使用前最重要的一项技术保障[1]。1批签发管理制度的建立1992年,WHO推荐疫苗生产国实施批签发制度,1998年进一步将其作为生物制品管理的6项关键职能之一。我国于2001年开始试行批签发制度[2],
The issuance of a biological product batch is the result of the examination and testing conducted by the national drug regulatory agency or its authorized unit according to the batch production verification record. The system of releasing the biological product to be marketed and put on sale is the most important one before the large-scale use of the biological product Item Technical Support [1]. Establishment of a batch issuance management system In 1992, the WHO recommended that the vaccine producing countries implement the batch issuance system and further consider it as one of the six key functions of biological product management in 1998. In 2001, China began the pilot approval system [2]